Pd-1 antibody
AssigneeUCB Pharma S.A.
InventorKerry Louise Tyson
Life of this patent
Estimating the term…
Abstract
A humanised agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.
Claims27
A humanised agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO:
- 33)
A humanised agonistic antibody which binds human PD-1 comprising a light chain wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3 and the light chain framework region is derived from human sub-group sequence VK2 4-1-1 A18+JK2 (SEQ ID NO:31)
A humanised agonistic antibody which binds human PD-1 having a heavy chain comprising a sequence given in SEQ ID NO:23 and a light chain comprising a sequence given in SEQ ID NO:15.
(canceled)
(canceled)
Dependencies are inferred from the claim text.